Holen Sie sich die Stockscreener-App
1.52
5.00%
-0.08
Handel nachbörslich:
1.52
Opko Health Inc Aktie (OPK) Neueste Nachrichten
OPKO Health, Inc.'s (NASDAQ:OPK) CEO Phillip Frost is the most upbeat insider, and their holdings increased by 9.6% last week - Simply Wall St
Here's Why You Should Retain OPKO Health Stock in Your Portfolio - MSN
OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024 - The Manila Times
OPKO Health (NASDAQ:OPK) Shares Up 4.7%What's Next? - MarketBeat
SECONDARY HYPERPARATHYROIDISM MARKET TO WITNESS UPSURGE - openPR
Us Prostate Cancer Instruments And Test Market Report: - openPR
With 50% ownership, OPKO Health, Inc. (NASDAQ:OPK) insiders have a lot riding on the company's future - Yahoo Finance
Hypopituitarism Market Forecasted to Surge in Coming Years, - openPR
35,157 Shares in OPKO Health, Inc. (NASDAQ:OPK) Bought by Algert Global LLC - Defense World
Renaissance Technologies LLC Cuts Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK) - Defense World
OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies - MSN
OPKO Health (NASDAQ:OPK) Stock Price Up 4.1%Time to Buy? - MarketBeat
Squarepoint Ops LLC Invests $592,000 in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Recent Analysts’ Ratings Updates for OPKO Health (OPK) - Defense World
Hsbc Holdings PLC Sells 28,560 Shares of OPKO Health, Inc. (NASDAQ:OPK) - Defense World
NextPlat expands OPKO e-commerce deal to Japan By Investing.com - Investing.com South Africa
ModeX secures additional $35 million for antibody research By Investing.com - Investing.com South Africa
Significant E-Commerce Expansions - Trend Hunter
ModeX secures additional $35 million for antibody research - Investing.com
NextPlat expands OPKO e-commerce deal to Japan - Investing.com India
OPKO Health's (OPK) ModeX Therapeutics Secures $35M BARDA Supplement - StreetInsider.com
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program - StockTitan
OPKO Health (NASDAQ:OPK) Trading Up 5% - MarketBeat
Labcorp’s $237.5 Million Acquisition of Assets of OPKO Health - Global Legal Chronicle
Opko Health Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
OPK’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Upward Trajectory: Opko Health Inc (OPK) Posts a Gaine, Closing at 1.52 - The Dwinnex
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data - MSN
Opko Health stock maintains Buy rating from H.C. Wainwright on positive data - Investing.com Canada
OPKO Health's (OPK) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
OPKO Health (NASDAQ:OPK) Receives "Buy" Rating from HC Wainwright - MarketBeat
Entera Bio and OPKO Health report promising obesity treatment study By Investing.com - Investing.com Australia
Entera Bio and OPKO Health report promising obesity treatment study - Investing.com
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide - EIN News
OPKO Health (NASDAQ:OPK) Trading Down 2% - MarketBeat
ModeX Therapeutics appoints new Chief Medical Officer By Investing.com - Investing.com Canada
OPKO Health (NASDAQ:OPK) Shares Gap Down to $1.48 - MarketBeat
OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development - XM
ModeX Therapeutics appoints new Chief Medical Officer - Investing.com
OPKO Health's (OPK) ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development - StreetInsider.com
OPKO Health, Inc. (NASDAQ:OPK) Stake Boosted by Rubric Capital Management LP - MarketBeat
OPKO Health (NASDAQ:OPK) Rating Reiterated by Barrington Research - MarketBeat
Labcorp Stock Gains From Its Latest Acquisition of BioReference Health - MSN
HC Wainwright Reiterates “Buy” Rating for OPKO Health (NASDAQ:OPK) - Defense World
OPKO Health (NASDAQ:OPK) Stock Price Down 2.4% - MarketBeat
OPKO Health (NASDAQ:OPK) Given Overweight Rating at Piper Sandler - Defense World
Opko Health retains Buy rating from H.C. Wainwright post-asset sale - Investing.com Canada
Piper Sandler maintains Overweight rating on Opko Health shares on strong prospects - Investing.com Canada
Piper Sandler Reiterates Overweight Rating for OPKO Health (NASDAQ:OPK) - MarketBeat
LabCorp slashes workforce in Melbourne after $237.5 million acquisition - The Business Journals
OPKO Health (NASDAQ:OPK) Shares Gap Down to $1.64 - MarketBeat
1.94%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):